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Eosinophilic chronic rhinosinusitis (ECRS) and asthma were both long thought 
to be allergen-driven diseases given the prominent “Th2-type” inflammation in 
the majority of cases and association with other diseases of the “atopic 
march”.  A major flaw with this scenario has always been that a substantial 
proportion of patients with these diseases, and in particular many of those 
with most severe pathology, do not exhibit evidence of allergen sensitisation 
on skin-prick testing or specific IgE testing (1) (2).  While this observation 
does not exclude a possible role for Th2 cytokines and IgE, allergen-specific 
or otherwise, in both diseases, the past decade has seen a change in our 
mechanistic understanding of the immunopathology underlying eosinophilic 
airway disease from a paradigm where allergen-specific, T helper type-2 
(Th2) lymphocytes are the primary disease drivers to one in which production 
of cytokines by damaged respiratory epithelium is the primary driver for 
eosinophilic responses and possibly, but not inevitably, local IgE synthesis.  
These cytokines – in particular IL-25, IL-33 and TSLP - act to stimulate 
production of “Th2-type” cytokines from innate lymphoid cells (ILCs) in an 
antigen-independent manner, as well as from Th2 lymphocytes (3) (4). In 
addition there is evidence, at least from animal surrogates, that these 
cytokines can effect many of the aspects of airways remodelling deemed 
characteristic of asthma, such as neoangiogenesis (5).  A range of both 
endogenous, local stimuli as well as external, environmental stimuli can elicit 
epithelial release of these cytokines - one such category of stimuli is 
endogenous and environmental proteases. It is of particular interest that 
certain common, inhaled aeroallergens exhibit such protease activity.  As with 
other immune pathways, checkpoints and counter-balances exist to regulate 
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these powerful pro-inflammatory pathways and prevent pathological 
inflammation.  Of particular importance in this regard appear to be 
endogenous protease inhibitors (EPIs).  In ECRS and certain asthma 
endotypes it appears that a failure to regulate these pathways, leading to an 
imbalance between airways proteases and protease inhibitors, may be central 
to the disease pathology. 
 
Kouzaki and colleagues in their article in this issue advance our 
understanding of the significance of this imbalance between inhaled 
proteases and EPIs in patients with ECRS using a comprehensive series of 
experiments with ex vivo patient samples and a range of immunological 
models (6).  In particular they studied the EPIs cystatin A, a cysteine protease 
inhibitor, and SPINK5, a serine protease inhibitor.  They discovered lower 
expression of these EPIs in nasal tissue samples from patients with ECRS as 
compared to those with non-eosinophilic chronic rhinosinusitis (NECRS) or 
healthy controls. In cell culture experiments using cultured, human bronchial 
epithelial cells they went on to show that recombinant EPIs reduced the 
release of IL-25, IL-33 and TSLP by these cells following exposure to two 
common aeroallergens with protease activity, Alternaria and house dust mite, 
and protease from Staphylococcus aureus, a microbe commonly carried in the 
respiratory tract.  Conversely, siRNA knockdown of SPINK5 and/or cystatin A 
augmented the release of these cytokines in response to the protease stimuli.   
They additionally studied a murine surrogate of acute and chronic protease 
exposure involving intranasal instillation of a protease cocktail of both 
allergens and the staphylococcal protease. Treatment of the animals with 
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recombinant EPIs reduced nasal tissue concentrations of TSLP, IL-25 and IL-
33 produced in response to a single acute challenge with the protease 
cocktail.  Upon chronic regular exposure of the animals to this protease 
cocktail, addition of recombinant EPIs again reduced multiple indices of Th2-
type airways inflammation. In the absence of recombinant EPIs, nasal 
concentrations of the endogenous EPIs cystatin A and SPINK5 initially 
appropriately increased following exposure to the cocktail of exogenous 
proteases, but more prolonged exposure resulted in a significant decrease in 
the concentrations of both endogenous EPIs compared with controls. This 
suggests an environmental scenario in which excessive exposure to 
proteases may in certain individuals exhaust innate defences, resulting in the 
triggering of local inflammation and remodelling at least initially through 
innate, antigen-independent mechanisms. 
 
Fascinating though these findings are, they beg but do not address the more 
fundamental question of which problem comes first: impaired EPI expression 
resulting in greater susceptibility to environmental proteases or excessive 
exposure to such proteases eventually exhausting “normal” EPI expression. 
Both scenarios might of course co-exist.  Cellular regulation of EPI expression 
itself is poorly understood.  Netherton syndrome, due to inheritance of loss-of-
function mutations in both copies of SPINK5, causes dermatological 
pathology and also elevated IgE levels often with an eosinophilia, however 
such mutations are rare (7).  Importantly, there are associations between 
polymorphisms in EPIs such as SPINK5 and asthma, and these 
polymorphisms may provide a small contribution to the aetiology of these 
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eosinophilic airways diseases (8) (9).  Nevertheless, it seems more likely that 
excessive exposure to environmental factors explains marked reduction in 
airway concentrations of EPIs in patients with chronic, eosinophilic airways 
diseases.  In particular, chronic exposure to proteases appears to cause 
aberrant decreased concentrations of airway EPIs through an unknown 
mechanism that may be sensitive to further manipulation and be amenable to 
future pharmacotherapy. 
 
Although some inhaled aeroallergens have protease activity, it is notable that 
the authors’ cocktail included a bacterial protease.  There is a well-recognised 
association between nasal carriage of Staph. aureus and both severe asthma 
and severe rhinitis, and suggestive evidence that staphylococcal proteases 
may underpin this association (10) (11).  Many other microbes have been 
shown to be capable of producing proteases, for example Aspergillus 
fumigatus (4).  Interestingly nasal inflammatory responses to Alternaria have 
been described in individuals with negative skin-prick tests (12); such 
responses might be protease-, rather than IgE-mediated. One might speculate 
that microbes colonising the airways can chronically produce proteases that 
drive “Th2-type” inflammation rather than causing conventional clinical 
infection.  If this is the case then topical antimicrobials might have a role in 
treating diseases such as asthma and ECRS even in patients without 
evidence of conventional infection.   
Many of the individuals with ECRS in the study of Kouzaki and colleagues 
were indeed non-atopic and it would have been interesting to know whether 
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either atopic status or nasal carriage of Staph. aureus influenced nasal 
concentrations of EPIs within their ECRS subgroup.   
 
Ultimately, one may envisage a future in which manipulation of EPIs and/or 
protease inhibition may provide a novel therapeutic option in eosinophilic 
airways diseases (13), perhaps with measurement of sputum protease activity 
used as a biomarker to titrate therapy. 
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